Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Earlier from Xenitra
- Appendix 4E and Annual Report
- Xenitra Raises $1.5m to Accelerate High-Margin Sales Growth
- $5m Offtake Agreement Expands OTC-Medicine Business
- $12M offtake agreement with leading OTC-pharmaceutical
- $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra